HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

M.I. van Poelgeest, M.J. Welters, E.M. van Esch, L.F. Stynenbosch, G. Kerpershoek, E.L. van Persijn-van Meerten, M. van den Hende, M.J. Lowik, D.M. Berends-van Meer, L.M. Fathers, A.R. Valentijn, J. Oostendorp, G.J. Fleuren, C.J. Melief, G.G. Kenter, S.H. van der Burg

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Article number88
JournalJournal of Translational Medicine
Volume11
DOIs
Publication statusPublished - 2013

Cite this

van Poelgeest, M. I., Welters, M. J., van Esch, E. M., Stynenbosch, L. F., Kerpershoek, G., van Persijn-van Meerten, E. L., ... van der Burg, S. H. (2013). HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. Journal of Translational Medicine, 11, [88]. https://doi.org/10.1186/1479-5876-11-88